Suppr超能文献

Grb2、Src、Lck和ZAP-70的Src同源2(SH2)结构域拮抗剂。

Antagonists of the Src homology 2 (SH2) domains of Grb2, Src, Lck and ZAP-70.

作者信息

García-Echeverria C

机构信息

Oncology Research, Novartis Pharma AG, CH-4002, Basel, Switzerland.

出版信息

Curr Med Chem. 2001 Nov;8(13):1589-604. doi: 10.2174/0929867013371905.

Abstract

Src homology 2 (SH2) domains are protein modules that mediate intracellular protein-protein interactions in signal transduction pathways. The specific association of an SH2 domain with a phosphotyrosine-containing sequence of another protein induces a cascade of molecular interactions that effect a wide range of cellular processes. Alterations in these signaling pathways have been associated with the development and progression of a broad range of pathologies. Because of the regulatory role of SH2 domains in these signal transduction pathways, specific SH2 domains can be ideal targets for intervention with therapeutic agents in many different disease indications (e.g. cancer, osteoporosis, disorders of the immune and cardiovascular systems). Among the SH2 domains pursued as drug discovery targets in the last few years are those of Grb2, Src, Lck and ZAP-70. This review focuses on contributions in the design and synthesis of antagonists of these particular SH2 domains. Specific examples have been selected to illustrate how structure-based design approaches have been used to progress in this area of research.

摘要

Src同源2(SH2)结构域是在信号转导途径中介导细胞内蛋白质-蛋白质相互作用的蛋白质模块。SH2结构域与另一种蛋白质的含磷酸酪氨酸序列的特异性结合会引发一系列分子相互作用,从而影响广泛的细胞过程。这些信号通路的改变与多种病理状况的发生和发展有关。由于SH2结构域在这些信号转导途径中的调节作用,特定的SH2结构域可能成为许多不同疾病适应症(如癌症、骨质疏松症、免疫和心血管系统疾病)中治疗药物干预的理想靶点。在过去几年中作为药物发现靶点研究的SH2结构域包括Grb2、Src、Lck和ZAP-70的SH2结构域。本综述重点关注这些特定SH2结构域拮抗剂设计和合成方面的贡献。已选择具体实例来说明基于结构的设计方法如何在该研究领域取得进展。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验